H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $20 from $32 and keeps a Buy rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance downgraded to Market Perform from Outperform at Citizens JMP
- Iovance Biotherapeutics Reports Q1 2025 Financial Results
- Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential
- Closing Bell Movers: Pinterest jumps 15%, Toast up 7% after earnings
- Iovance Biotherapeutics reports Q1 EPS (36c), consensus (23c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue